Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lenti-miR449a
- Development stage
- Preclinical
- Lead developer
- AptamiR Therapeutics
- Modality
- Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
lenti-miR449a is a lentiviral vector-based gene therapy designed to overexpress microRNA-449a (miR-449a). In the context of bladder cancer research, it is used to down-regulate the androgen receptor (AR) signaling pathway. miR-449a acts as a tumor suppressor by targeting the expression of AR and its downstream effector, prostate-specific antigen (PSA), as well as inducing G0/G1 cell cycle arrest through the inhibition of HDAC1 or Rb phosphorylation. By increasing miR-449a levels, lenti-miR449a inhibits the proliferation and viability of AR-positive bladder cancer cells.
- Other names
- lentivirus-miR-449alentivirus-miR449alentivirus-miR 449amiR-449a lentivirusmiR449a lentivirusmiR 449a lentivirus
02
Targets
Acyl-CoA synthetase long-chain family member 4 mRNA 3' UTRCell division cycle 25A mRNA 3' untranslated regionCCND1 (Cyclin D1)Cyclin-dependent kinase 6 mRNA 3' untranslated region (CDK6 mRNA 3' UTR)LEF1Plakophilin 4 mRNA 3' untranslated region (PKP4 mRNA 3' UTR)TSEN15 (tRNA-splicing endonuclease subunit 15)AR (Adrenergic receptors)
Beyond the preview
Go deeper on lenti-miR449a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lenti-miR449a.